Tests magnesium to prevent new irregular heartbeat in critically ill patients
Tests magnesium sulfate or placebo in adults in intensive care to prevent atrial fibrillation.
Plain-language title generated from the registry record
Registry title: Magnesium Prophylaxis for the Prevention of New-Onset Atrial Fibrillation in Critically Ill Patients
Key facts
- Where
- Hamilton, Kingston, and Ottawa, CanadaSee the 4 sites
- Phase
- Phase 4
Where in Canada
- St. Joseph's Healthcare HamiltonHamilton, CanadaNot yet recruiting
- Kingston Health Sciences CentreKingston, CanadaTaking people
- The Ottawa Hospital - Civic CampusOttawa, CanadaNot yet recruiting
- The Ottawa Hospital - General CampusOttawa, CanadaNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Dr. Stephanie Sibley
- Trial code
- NCT05829317
- Record updated
- 22 September 2025
- Original description
A double-blind, multi-centre, randomized, placebo-controlled, feasibility pilot trial in the prevention of new onset atrial fibrillation of critically ill patients admitted to an ICU.Read full original descriptionShow less
Parenteral Magnesium Prophylaxis for the Prevention of New-Onset Atrial Fibrillation in Critically Ill Patients - a Pilot Feasibility Study
A double-blind, multi-centre, randomized, placebo-controlled, feasibility pilot trial in the prevention of new onset atrial fibrillation of critically ill patients admitted to an ICU.
Inclusion: Age ≥18 years; Admitted to an ICU with one or more of the following:; Non-invasive ventilation (including CPAP, Bipap and high flow oxygen (>10L/min) or invasive mechanical ventilation with an expected duration >24 hours for respiratory failure (hypercarbic or hypoxic); Vasopressor or inotropic support with an expected duration of >24 hours; Cardiac arrest; Continuous cardiac monitoring.
Exclusion: Receiving ICU intervention (Non-invasive ventilation (including high flow nasal canula), invasive mechanical ventilation or inotropic support) for >18 hours; Receiving IMV for airway protection only (for example, isolated head trauma); Patients receiving dialysis; Previously enrolled in this trial; Cardiac surgery patients; Patients requiring parenteral magnesium therapy (e.g. pre-eclampsia, asthma); Positive pregnancy test (females <50 years old); Active atrial fibrillation at the time of enrolment; On oral or continuous infusion of Amiodarone; Unlikely to survive >24 hours or palliative patients; Treating physician refuses enrollment.